Revenue segments as reported by the company.

Protein Sciences

Diagnostics and Genomics

lntersegment

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bio-Techne

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Bio-Techne Corp reports steady Q3 revenue growth amidst China challenges

Bio-Techne Corp reported steady Q3 revenue growth despite challenges in China and temporary headwinds. The company is focused on driving growth in strategic platforms and expanding key franchises. Succession planning and margin improvement are key areas of focus for future growth.

Bio-Techne reports strong Q2 earnings, eyes growth in diagnostics

Bio-Techne's Q2 2023 earnings call highlighted solid performance, strategic strengths in key segments, challenges in ordering patterns, and growth opportunities in diagnostics and research.
The company's focus on innovation, cost management, and strategic investments positions it well for future growth and reaching ambitious revenue targets by FY 2026.
Despite short-term challenges in certain markets, Bio-Techne remains optimistic about its long-term growth prospects and transparent communication with investors.
With a strong financial performance, expanding product portfolio, and a focus on high-growth areas, Bio-Techne is poised for sustained success and market leadership.

Bio-Techne reports solid Q3 performance, eyes growth in key segments

Bio-Techne's Q3 performance showcased strengths in key segments like ExoDx Prostate test demand and GMP proteins, despite challenges in certain markets and OEM destocking dynamics. The company's strategic focus on expanding the Wilson Wolf franchise and driving growth in ACD and key segments like cell and gene therapy position it well for future success. Addressing challenges and capitalizing on growth opportunities will be pivotal for Bio-Techne's continued expansion and market leadership.

Bio-Techne (TECH) excels in Q4, eyes growth amid challenges

Bio-Techne (TECH) reports strong revenue growth and promising future prospects.
Strategic focus on key segments like cell and gene therapy and spatial biology.
Challenges in macroenvironment and funding uncertainties require cautious navigation.
Active M&A strategy and investments to drive growth and market dominance.

Bio-Techne reports steady Q1 growth amid industry challenges

Bio-Techne's Q1 performance showed resilience amidst industry challenges, with a focus on key growth areas and regions. While facing headwinds, the company remains cautiously optimistic about future prospects, emphasizing long-term growth opportunities and productivity measures.

Bio-Techne reports Q2 revenue growth amidst China challenges and opportunities

Bio-Techne's Q2 performance reflects revenue growth and operational efficiency, despite challenges.
Strengths lie in core businesses, Diagnostics and Genomics growth, and record consumables usage in China.
Challenges include market declines, funding constraints, and headwinds in biopharma and academic markets.
Opportunities exist in market normalization, China growth, new product releases, and M&A strategies.

Bio-Techne surpasses Q3 expectations, eyes growth in emerging markets

Bio-Techne's Q3 showcased strong financial performance, with revenue growth and margin expansion across key segments, setting the stage for continued success.
The company's focus on innovation, awards recognition, and strategic market positioning in high-growth areas like cell and gene therapy underpin its competitive strength.
While facing challenges in certain regions and production constraints, Bio-Techne's proactive approach to scaling up manufacturing and diversifying markets positions it well for future growth.
With a clear emphasis on operational efficiency, market expansion, and strategic investments, Bio-Techne is poised for sustained success and value creation for stakeholders.

Bio-Techne reports solid Q4 performance and eyes market recovery

Bio-Techne's Q4 2024 performance reflects resilience and potential for accelerated growth as markets recover in fiscal year 2025.
Strategic leadership additions, productivity initiatives, and market recovery expectations position the company for future success.
Challenges such as capacity constraints and funding environments require strategic management for sustained growth.
Opportunities lie in market recovery, margin improvement, and growth prospects across different segments for Bio-Techne in the coming year.

Bio-Techne reports solid Q1 earnings, eyes growth in biotech markets

Bio-Techne (TECH) delivered solid Q1 2025 results with organic revenue growth, strong segment performances, and a focus on sustainability and strategic partnerships.
While facing challenges in certain markets, the company's emphasis on cost containment and productivity optimization bodes well for future profitability and resilience.
With a positive outlook for growth and opportunities in key segments, Bio-Techne is poised for continued success and market leadership in the biotech industry.
Investors can be optimistic about Bio-Techne's performance, strategic initiatives, and growth prospects, supported by a strong financial foundation and market positioning.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.

MINNEAPOLIS, Sept. 22, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope™ technology with release of the new RNA-Protein Co-Detection Assays. The RNAscope technology is an advanced in situ...

Bio-Techne Announces Commercial Release Of New Co-Detection Assays For Simultaneous Detection Of RNA And Protein On The Same Sample

MINNEAPOLIS, Sept. 21, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that the B-MoGen Biotechnologies portfolio of genome engineering services, GMP therapeutic manufacturing services, and its proprietary transposon-transposase gene transfer system, TcBuster™,...

Bio-Techne Rebrands B-MoGen Biotechnologies As Part Of The R&D Systems Product Portfolio

MINNEAPOLIS, Sept. 17, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and QIAGEN N.V.

Bio-Techne and QIAGEN Announce Expansion and Extension of Exosome Partnership

Genmab - ADR

Innoviva

Mersana Therapeutics

Novavax

Regeneron Pharmaceuticals

Vanda Pharmaceuticals

XBiotech

These are the biotech stocks with the best value, fastest growth, and most momentum for Q4 2020.

Top Biotech Stocks for Q4 2020

MINNEAPOLIS, Aug. 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the release of the SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody, which binds to the SARS-CoV-2 spike receptor binding domain (RBD) and blocks the virus from binding to its host.

Bio-Techne Announces Release of a New SARS-CoV-1/2 Spike RBD LlaMABody™ Recombinant Antibody that Blocks Viral Entry

Bio-Techne's (TECH) CEO Chuck Kummeth on Q4 2020 Results - Earnings Call Transcript

Shares of Bio-Techne (NASDAQ:TECH) were unchanged after the company reported Q4 results.

Recap: Bio-Techne Q4 Earnings

MINNEAPOLIS, Aug. 4, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ended June 30, 2020.

Bio-Techne Releases Fourth Quarter Fiscal 2020 Results

MINNEAPOLIS, Aug. 3, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Julie L.

Bio-Techne Announces Appointment Of Julie L. Bushman To Its Board Of Directors

MINNEAPOLIS and NEW YORK, Aug. 3, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the COVID-SeroIndex, a Kantaro.

Bio-Techne And Kantaro Biosciences To Launch A Quantitative Research Use Only COVID-19 Serology Test

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Techne (TECH) Q4 Earnings Expected to Decline

Bio-Techne (TECH) is expected to report earnings on Aug. 4. The stock is now trading 1% below the 282.62 buy point from a second-stage cup without handle that it cleared earlier.

Earnings Season Watch List: Bio-Techne Nears Buy Point

MINNEAPOLIS, July 21, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed validation testing for COVID-19 caused by the novel coronavirus (SARS-CoV-2) and now offers the ExoCovid-19 test for detection of the.

Bio-Techne Announces Launch Of ExoCovid-19 Test For Detection Of SARS-CoV-2 In Patient Samples

MINNEAPOLIS, July 20, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the RNAscope™ platform with the release of the miRNAscope™ Assay. The RNAscope technology is an advanced in situ hybridization assay for the spatial visualization of.

Bio-Techne Announces Commercial Release Of New Assay For Detecting ASOs, miRNAs, And siRNAs In Tissue

MINNEAPOLIS, June 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with ZERO – The End of Prostate Cancer, the leading national nonprofit organization in the fight against prostate...

Bio-Techne And ZERO - The End Of Prostate Cancer Announce Partnership To Fund Education And Awareness Campaigns To Empower Men With Prostate Cancer

MINNEAPOLIS, June 8, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the release of GMP ProDots™ Proteins to support cell and gene therapy manufacturing workflows. GMP ProDots™ Proteins address a critical need to precisely dose and safely add essential proteins...

Bio-Techne Announces Release of GMP ProDots Proteins to Support Cell and Gene Therapy Manufacturing Workflows

Ligand Pharmaceuticals

LGND vs. TECH: Which Stock Is the Better Value Option?

LGND or TECH: Which Is the Better Value Stock Right Now?

MINNEAPOLIS and NEW YORK, May 19, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced a partnership to initiate scaled manufacturing and distribution of...

Bio-Techne And Kantaro Biosciences Announce Partnership To Develop And Scale Production Of COVID-19 Serology Test

LGND vs. TECH: Which Stock Should Value Investors Buy Now?

Bio-Techne Corporation (TECH) CEO Chuck Kummeth on Q3 2020 Results - Earnings Call Transcript

Techne (TECH) delivered earnings and revenue surprises of 23.01% and 5.31%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Techne (TECH) Tops Q3 Earnings and Revenue Estimates

Earnings Preview: Techne (TECH) Q3 Earnings Expected to Decline

Alexion Pharma

Biogen

Johnson & Johnson

Novo Nordisk

Biotech and drug manufacturing companies with the strength to weather further coronavirus storms.

5 Pharmaceutical Companies to Consider as Coronavirus Vaccine Race Heats Up

REGN vs. TECH: Which Stock Is the Better Value Option?

REGN vs. TECH: Which Stock Should Value Investors Buy Now?

Bio-Techne Corporation (TECH) CEO Chuck Kummeth on Q2 2020 Results - Earnings Call Transcript

News for Bio-Techne Stock (TECH)